Is aging a barrier to reprogramming? Lessons from induced pluripotent stem cells

The discovery of induced pluripotent stem cells (iPSCs) has the potential to revolutionize the field of regenerative medicine. In the past few years, iPSCs have been the subject of intensive research towards their application in disease modeling and drug screening. In the future, these cells may be...

Full description

Saved in:
Bibliographic Details
Published in:Biogerontology (Dordrecht) Vol. 14; no. 6; pp. 591 - 602
Main Authors: Phanthong, Phetcharat, Raveh-Amit, Hadas, Li, Tong, Kitiyanant, Yindee, Dinnyes, Andras
Format: Journal Article
Language:English
Published: Dordrecht Springer Netherlands 01.12.2013
Springer Nature B.V
Subjects:
Age Factors
Aging
Aging - genetics
Aging - metabolism
Aging - pathology
Aging, Premature - genetics
Aging, Premature - metabolism
Aging, Premature - pathology
Aging, Premature - physiopathology
Aging, Premature - therapy
Anatomical systems
Animals
Biomedical and Life Sciences
Cell Biology
Cellular Reprogramming
Cellular Senescence
Deoxyribonucleic acid
Developmental Biology
DNA
Gene Expression Regulation, Developmental
Genetic Therapy - methods
Genomes
Genomics
Geriatrics/Gerontology
Humans
Induced Pluripotent Stem Cells - metabolism
Induced Pluripotent Stem Cells - pathology
Life Sciences
Medical screening
Medicine
Nuclear Transfer Techniques
Regenerative medicine
Regenerative Medicine - methods
Research applications
Review Article
Senescence
Stem cells
Telomerase
Tumors
Hungary
Thailand
Aging
Premature aging
Nuclear reprogramming
Induced pluripotent stem cells
Cellular senescence
ISSN:1389-5729, 1573-6768, 1573-6768
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery of induced pluripotent stem cells (iPSCs) has the potential to revolutionize the field of regenerative medicine. In the past few years, iPSCs have been the subject of intensive research towards their application in disease modeling and drug screening. In the future, these cells may be applied in cell therapy to replace or regenerate tissues by autologous transplantation. However, two major hurdles need to be resolved in order to reach the later goal: the low reprogramming efficiency and the safety risks, such as the integration of foreign DNA into the genome of the cells and the tumor formation potential arising from transplantation of residual undifferentiated cells. Recently, aging emerged as one of the barriers that accounts, at least in part, for the low reprogramming efficiency of bona fide iPSCs. Here, we review the molecular pathways linking aging and reprogramming along with the unanswered questions in the field. We discuss whether reprogramming rejuvenates the molecular and cellular features associated with age, and present the recent advances with iPSC-based models, contributing to our understanding of physiological and premature aging.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1389-5729
1573-6768
1573-6768
DOI:10.1007/s10522-013-9455-2